Thursday, July 4, 2019

Drug Delivery Systems Market Worth Over US$ 900 Bn By 2025

Drug Delivery Systems Market: Snapshot

Drug delivery includes formulations, technologies, methods, and systems for transferring an active pharmaceutical ingredients into the body to safely provide therapeutic effect. The global drug delivery systems market was valued approximately US$ 510 Bn in 2016 and is anticipated to expand at a CAGR of over 6.9% from 2017 to 2025 to reach approximately US$ 900 Bn by 2025. Increase in demand for self-administration and home health care devices are likely to fuel expansion of the global drug delivery systems market from 2017 to 2025.


Continuous innovations in the global drug delivery systems market is creating opportunities for major and local manufacturers to develop wide product portfolio. Additionally, collaborations among major market players for superior technological advancements in drug delivery offerings is likely to drive the global drug delivery systems market during the forecast period. Using nanotechnology, the drug can be targeted to a precise location, which makes drugs more effective and reduce the chances of possible side effects. Major manufacturers operating in the market are involved in continuous research & development activities to expand their already wide product portfolio. For instance, on September 2017, Baxter International Inc. announced the launch of DeviceVue, an asset tracking system for sigma spectrum infusion system whereas, emerging players operating in the market are also focusing on introducing new versions of their existing drug delivery devices. Continuous expansion of drug delivery systems offering in high throughput along with reduced waiting time and improved result specificity are likely to drive the global drug delivery systems during the forecast period. However, high cost associated with treatment and increase in drug recalls are likely to restrain the global drug delivery systems market during the forecast period.


The global drug delivery systems market has been segmented based on delivery system, application, route of administration, and geography. In terms of delivery system, the targeted drug delivery segment is projected to continue its dominance during the forecast period followed by the polymeric drug delivery segment. Introduction of new drug delivery devices such as SmartDose wearable injector and increase in demand for targeted and low dose frequency drug delivery is likely to propel the segment. Based on application, oncology was the leading revenue generating segment in 2016 and it is likely to continue its dominance during the forecast period due to the increase in prevalence of various types of cancer. According to WHO report, in the year 2015, around 70% of cancer-related deaths occurred in low- and middle- income countries. The infectious diseases segment is likely to lose market share during the forecast period owing rise in preference to develop oncology and diabetes drug delivery system by manufactures. In terms of route of administration, injectable dominated the market in 2016 and is likely to account for a leading share during the forecast period.
Geographically, North America accounted for a leading share of the global drug delivery system market in 2016. However, rise in research & development expenses for advanced drug delivery devices in the U.S. is key concern area among key players. The market in Asia Pacific is projected to gain share during the forecast period and is likely to be key revenue generator in the next few years. Initiatives by local governments for self-sufficiency in manufacturing pharmaceuticals and prevalence of various diseases in countries such as Brazil, South Africa, Saudi Arabia, etc. are anticipated to boost market in Latin America and Middle East & Africa.



Key companies operating in the global drug delivery systems market and profiled in the report include AstraZeneca plc., Bayer AG, Pfizer, Inc., Novartis AG, Amgen Inc., Johnson and Johnson Services, Inc., Baxter International, Inc., Boston Scientific Corporation, and Becton, Dickinson & Company. These players adopt organic and in-organic growth strategies to expand their product offerings, strengthen their geographical reach, increase customer base, and garner market share. For instance, in June 30, 2017, the F. Hoffmann-La Roche Ltd. acquired mySugr, a company that is dedicated to developing applications and software for diabetes care.

Wednesday, July 3, 2019

Clinical Rollators Market Latest Innovations, Future Scope and Market Trends

Global Clinical Rollators Market: Overview 

The global clinical rollators market has witnessed steady growth over the years with the rising technological advancements in developing rollator walker with lightweight and seat rollators. Clinical rollators are also known as wheeled walkers comprised of features in build shopping basket along with lightweight and height adjustable. Such rollators provide physical support to physically disabled patients, aged people, and diseased patients. Clinical rollators helps in enhancing the ability of disabled patients to stand or move independently.

An upcoming report on the global clinical rollators market by Transparency Market Research promises to be crucial source of information for stakeholders looking to strengthen their foothold in the market. The report would enable them to gain proper insight into the growth drivers and restraints. The exhaustive information in the report would unravel the opportunities and pitfalls in the market. The report runs through multiple standpoints such as trends, competitive landscape, product, application, and regional segments to understand if the global clinical rollators market holds out solid promise.

Global Clinical Rollators Market: Key Trends 

Rising cases of arthritis and gait, growing population suffering from various types of diseases, and increasing adoption of advanced mobility products are believed to be driving the global clinical rollators market. Clinical rollators can be found in the form of four-wheel, bariatric rollators, and three-wheel. Along with these, rising demand for hospital-based and home-based patient care services, and increasing end-users such as clinics, hospitals, and hospital-based patient care centers are also expected to fuel the global clinical rollators market. Moreover, a trend in using technologically advanced clinical rollators for comfortable sitting options is also projected to propel the global clinical rollators market.


Furthermore, rising incidences of accident, growing demand for mobility in day-to-day life, and increasing need for clinical rollators during post-treatment recovery phases are expected to boost the global clinical rollators market. Apart from this, the incorporation of advanced technology in clinical rollators help in developing rollators with digital software and advanced sensors. All such features are anticipated to fuel demand in the global clinical rollators market.

Global Clinical Rollators Market: Regional Outlook 

With respect to geography, North America is expected to lead the global clinical rollators market as the region has seen rapid technological advancements. Increasing cases of chronic disorders, burgeoning population, and growing demand from disabled patients to move independently could also be responsible for fueling the clinical rollators market in this region. Other prominent regions in the global clinical rollators market are APAC, and EMEA. Rising incidence of accidents, and rapid improving healthcare infrastructure are expected to boost the global clinical rollators market in these regions.


Global Clinical Rollators Market: Competitive Dynamics 

Some of the prominent players operating in the global clinical rollators market are Benmor Medical, Evolution Technologies, Briggs Healthcare, HUMAN CARE, Carex Health Brands, and GF Health Products. The competition among competitors is rising based on their investments in research and development activities for developing innovative rollator walkers. The upcoming report studies competitor’s product portfolios, key strategies, and sales and revenues in the near term.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Drug Repurposing Market to Witness Robust Expansion throughout the Forecast 2018 to 2027

Global Drug Repurposing Market: Overview 

National Institute of Health (NIH), of the US Department of Health offers the drug repurposing and gaining new approvals along with widening usage of the drug repurposing. It has numerous potential opportunities for growth by catering the unmet medical needs with some cost-effective solutions as alternative to the expensive drugs.

The global drug repurposing market report from Transparency market research offers the insights on the market dynamics. The report briefs the factors such as drivers, opportunities, trends, and restrains. The drug repurposing market report represents extensive outlook of the key players such as Porter’s five forces and SWOT analysis. Also, it provides the information such as merger and acquisition (M&A), research & development (R&D), and investment and profit analysis of the key players dominating the drug repurposing market.  


Global Drug Repurposing Market: Drivers and Restraints 

Need of the low investment in terms of time and money is fuelling demand for the drug repurposing which is leading to increase number of pipeline products is propelling growth of the drug repurposing market. Additionally, some of the other factors propelling growth of the global drug repurposing market are low research cost and easy bioavailability is propelling its growth from past few years. Additionally, it is a bio-based products which lowers the possibility of side effects and enhances the potential to reposition. This factor is propelling growth of the global drug repurposing market. However, lack of funding and limited information is restraining growth of the global drug repurposing market.     


Global Drug Repurposing Market: Geographical Analysis 

Based on geography, the market has been segmented into the following regions: North America, Europe, Latin America, Asia Pacific, Latin America and the Middle East and Africa. Of these, North America is expected to dominate the drug repurposing market. This growth is attributable to the high rates of expenses on research and treatments. 


Global Drug Repurposing Market: Companies Mentioned 


Some of the key players operating in the global drug repurposing market are Astellas Pharma, Biovista, Novartis, AbbVie, Pfizer, Allergan, and NuMedii. 

Pulse Lavage Systems Market Global Outlook and Overview 2018-2026

Pulsed lavage is a type of mechanical hydrotherapy that uses an irrigating solution under pressure produced by an electrically powered device. This pressurized pulsed solution irrigates and debrides wounds of necrotic tissue. Irrigation under pressure may be delivered concurrently with suction to remove both irrigation solution and wound debris, which helps to improve granulation tissue growth without damaging the underlying normal tissues. Additionally, negative pressure created by the suction stimulates granulation and helps in speedy recovery of the wound. Pulsed lavage is used in wound cleansing to remove debris and infectious agents from a wound’s surface. This type of wound cleansing is also known as pulsatile lavage, mechanical lavage, high-pressure irrigation, lavage, jet lavage, or mechanical irrigation. This high-pressure wound irrigation system is commonly used in operating rooms and wound care facilities.


The global pulse lavage systems market is projected to grow at a rapid pace in the next few years due to rise in the number of surgical procedures, technological advancements in development of surgical tools, surge in number of orthopedic procedures, increase in geriatric population, and rise in sports and road accident injuries. Growing medical tourism and opportunities in developing economies also contribute to the growth of the global pulse lavage systems market. However, delay in wound healing due to high pressure irrigation acts as restraint of the market.


The global pulse lavage systems market can be segmented based on product type, usability, application, power source, and end-user. In terms of product type, the market can be bifurcated into pulse lavage devices & components and accessories. Based on usability, the global pulse lavage systems market can be categorized into disposable pulse lavage systems, semi-disposable pulse lavage systems, and reusable pulse lavage systems. The disposable lavage systems segment accounted for the largest market share in 2017, as these systems do not need maintenance and have low chances of cross-contamination. In terms of application, the market can be classified into orthopedics, wound care, and trauma. The orthopedics segment accounted for the largest market share and is expected to grow at a faster CAGR during the forecast period due to rise in prevalence of bone disorders such as osteoarthritis because of increase in geriatric population and obesity rates. Based on power source, the global pulse lavage systems market can be divided into battery-powered, gas-powered, and AC-powered. The battery-powered segment accounted for the largest market share in 2017 and is estimated to expand at a faster CAGR due to high demand for battery powered devices among end-users owing to high energy storage capabilities and low maintenance cost. In terms of end-user, the market can be categorized into hospitals & clinics and long-term care facilities. The hospitals & clinics segment dominated the global pulse lavage systems market in 2017 due to increase in admissions in hospitals for surgical procedures and wound care.


In terms of region, the global pulse lavage systems market can be segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America accounted for the largest share of the global market in 2017 due to increase in the geriatric population, rise in prevalence of bone disorders, surge in orthopedic procedures, and relatively greater access to health care. Asia Pacific is projected to be the fastest growing market due to high government focus on health care sector, increase in the geriatric population, rise in prevalence of chronic diseases, and economic growth in several countries.


Key players operating in the global pulse lavage systems market include Smith & Nephew plc, Stryker Corporation, MicroAire Surgical Instruments, LLC, Zimmer Biomet, Mölnlycke Health Care, Corin Orthopaedics Holding Ltd., Heraeus Holding GmbH, C. R. Bard, Inc., Judd Medical Ltd., and Atlantic Surgical Ltd.

Plaque Psoriasis Treatment Market Size, Share & Trend | Industry Analysis Report, 2026

Plaque psoriasis is the most common type of psoriasis and accounts for 80% to 90% cases of total psoriasis. Plaque psoriasis is an autoimmune condition, wherein thick, red patches appear on the skin. These plaques commonly appear on the knees, scalp, and elbows; however, these can also appear on other body part. These are itchy, painful, and can bleed. The exact cause of plaque psoriasis is unknown. The triggers of psoriasis include infections, severe sunburns, stress, smoking, alcohol consumption, obesity, dry skin, and certain medications. The common symptoms of plaque psoriasis include itching, pain, stinging sensation, and skin tightness. Diagnosis of plaque psoriasis is usually done with thorough skin examination. Occasionally, biopsy is also recommended to confirm the condition. Rise in prevalence of psoriasis across the globe, increase in research expenditure in developing countries, high level of unmet clinical needs in patients with psoriasis, surge in awareness about the condition, and favorable reimbursement policies are the major factors projected to drive the global plaque psoriasis treatment market during the forecast period. However, there is no disease modifying treatment available for the conditions and current treatment provides symptomatic relief only. This factor acts as a major restraint of the global plaque psoriasis treatment market.


The global plaque psoriasis treatment market can be segmented based on therapy, drug class, and region. In terms of therapy, the plaque psoriasis treatment market can be classified into topical therapy, phototherapy, systemic agents, and biologic therapies. The topical therapy segment dominated the market in 2017 and is projected to sustain its leadership position during the forecast period. This is because topical therapy is considered first line of treatment for plaque psoriasis. Phototherapy involves exposing skin to UV light under medical supervision. Phototherapy and systemic agents are usually prescribed when topical therapy is inadequate. Based on drug class, the global plaque psoriasis treatment market can be categorized into TNF-α inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors. The TNF-α inhibitors segment dominated the market in 2017 due to its safety profile and significant usage in the treatment of plaque psoriasis. The segment is expected to sustain its leadership position between 2018 and 2026. TNF-α inhibitors block body’s response to TNF, a protein produced by white blood cells, thereby suppressing inflammation. These are also used in the treatment of rheumatoid arthritis (RA), Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, and psoriasis.


In terms of region, the global plaque psoriasis treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for significant share of the global market during the forecast period. Rise in prevalence of plaque psoriasis in the U.S. and rich pipeline of drugs are the major factors anticipated to propel the market in North America from 2018 to 2026. According to the National Psoriasis Foundation, nearly 7.5 million people in the U.S. suffer from psoriasis, and plaque psoriasis is the most common type of the disease. According to the World Psoriasis Day consortium, 125 million people suffer from psoriasis across the globe. The plaque psoriasis treatment market in Asia Pacific is expected to expand at a high CAGR between 2018 and 2026. This can be attributed to increase in research expenditure and rise in awareness about the disease among the population.



Key players operating in the global plaque psoriasis treatment market are AbbVie, Inc., Pfizer, Inc., LEO Pharma A/S, Johnson & Johnson Services, Inc., Eli Lilly and Company, UCB S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Merck & Co., Inc., and Novartis AG.

Eye Cancer Treatment Market Share and Growth Factors Impact Analysis 2018 – 2026

Eye cancer, also known as ocular cancer, occurs in the eye of children and adults. It is in the form of tumor which starts in and around the eye. There are two types of eye cancer. Primary intraocular cancer starts in the eyeballs. Primary intraocular melanoma is the most common type followed by primary intraocular lymphoma. Retinoblastoma is the most common form of primary intraocular cancer which mostly occurs in children. Secondary intraocular cancer is a metastatic cancer which starts from other parts of the body and spreads to the eyes. Secondary intraocular cancer is more common than primary intraocular cancer and is often metastatic form of breast and lung cancers. Risk of prevalence of an eye cancer is higher in Caucasians than in people from Asia or African Americans. People with certain inherited conditions such as dysplastic nevus syndrome, BAP1 cancer syndrome, and other conditions are more prone to suffer from eye cancer.


According to American Cancer Society estimates, there would be 3,360 new eye and orbit cancer cases, with 1, 860 in men and 1,500 in women, in 2019. Additionally, in the same year, 370 deaths are estimated to occur due to eye and orbit cancers, comprising 200 men and 170 women. According to NHS, 750 cases of ocular cancer in the U.K. are diagnosed every year.


Increase in incidence of eye cancers, surge in health care expenditure, and rise in risk factors such as geriatric population drive the global eye cancer treatment market. Moreover, rise in demand for innovative treatments including advanced surgeries and high investment by governments are anticipated to propel the global market during the forecast period. Technological advancements resulting in continuous innovation and rise in awareness about eye cancer symptoms and their common causes are expected to augment the global eye cancer treatment market from 2018 to 2026. Increase in secondary compared to primary eye cancers is likely to boost the growth of the global market in the next few years. Initiatives by governments to focus on the development of surgeries and investment in health care are the other factors projected to boost market growth. However, high cost of treatment, unavailability of skilled professionals especially in developing countries, and side effects of the treatment restrain the global eye cancer treatment market. Longer time taken by ocular cancer drugs to get approved by the regulatory bodies also hampers the growth of the market.
The global eye cancer treatment market can be segmented based on type, treatment, end-user, and region. In terms of type, the global market can be classified into eyelid tumor, corneal cancer, uveal melanoma, and orbital tumor. Corneal cancer is a squamous cell carcinoma of the conjunctiva which is a malignant tumor that occurs in the lining of the eyeballs and eyelids. An orbital tumor occurs in the orbit which is the bony socket containing an eye. Orbit tumor could be malignant or benign and can be either primary or metastatic. Rhabdomyosarcoma and retinoblastoma are the two most life threatening orbital tumors. Retinoblastoma is a malignant tumor that starts from the retina. It is most common in children and often passed on from the parents. Eyelid tumor occurs in sebaceous gland known as the carcinoma of the eyelid. Uveal melanoma is a primary malignant tumor which is the most common eye cancer. Based on treatment, the global eye cancer treatment market can be categorized into surgery, radiation therapy, laser therapy, chemotherapy, and others. The others segment includes thermotherapy and brachytherapy. In terms of end-user, the global market can be divided into hospitals, clinics, and ambulatory surgical centers.


In terms of region, the global eye cancer treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Increase in demand for various surgical therapies for the treatment of eye cancers and rise in investment by governments in research & development of better eye cancer treatments boost the growth of the global eye cancer treatment market. North America dominated the global market in 2017 and the trend is projected to continue during the forecast period owing to the rising health care spending in the region and various innovative treatment offerings for eye cancer. Moreover, significant investments in research & development by companies and rise in awareness about eye cancers and their treatments are projected to boost the growth of the market in the U.S. Rise in the geriatric population is expected to increase the prevalence of primary eye cancers, as the risk increases with age. Europe is a prominent market for eye cancer treatments owing to the availability of treatment methods for eye cancer, high income of the population, and rise in demand for effective treatment. The eye cancer treatment market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. Rise in health care expenditure, rapidly expanding health care industry, and high unmet needs are likely to drive the market in the region during the forecast period. Technological advancements in the treatment of eye cancers and rise in disposal income are anticipated to propel the eye cancer treatment market in Asia Pacific during the forecast period. Additionally, the geriatric population is increasing in the highly populated counties in Asia Pacific which is a risk factor for eye cancers. This is projected to augment the global eye cancer treatment market during the forecast period. According to the American Academy of Ophthalmology, the incidence of uveal melanoma is lower in people from Asia and people of color.


Major players operating in the global eye cancer treatment market include Novartis AG, Spectrum Pharmaceuticals, Inc., GlaxoSmithKline plc, Bayer AG, Amgen, Inc., Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, AstraZeneca, F. Hoffmann-La Roche Ltd., Janssen Global Services, LLC, Sanofi, AbbVie, Inc., Pfizer, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, and Oncomed Pharmaceuticals.

Spinal Intervention Market : Size, Application Analysis, Regional Outlook, 2018 -2026

Spinal intervention involves the treatment of all maladies that afflict the spine. The aim of spinal intervention is pain management, wherein the focus is solely on the spine. The spine consists of 33 bones, which include 12 thoracic vertebrae, seven cervical vertebrae, five sacral vertebrae, five lumbar vertebrae, and four coccygeal vertebrae. The pedicle, which is a stub of a bone that connects the lamina to the vertebral body to form an arch, is crucial in spinal intervention, as it offers a safe and secured tunnel. Through this tunnel, the interventionist examining the spine can get safe access to the vertebral body for vertebroplasty, biopsy, and kyphoplasty. The pedicles located in the cervical area are small and they have poor access to the vertebral body. The size of the pedicles gradually increases from the upper thoracic spine i.e. T4 to the lower lumbar spine i.e. L5. Progressive angulation occurs toward the cervical area from T4. Therefore, both pedicle size and angulation are equally important while planning a transpedicular procedure during intervention.


Spinal decompression is performed to create sufficient space for the nerves in the spinal canal, thereby diminishing the pain caused by neural impingement. Spinal fusion is performed to stop movement at one or more vertebral segments so as to relieve the pain and correct the spinal instability. The aim of spinal fusion is to unwind the spinal nerves that cause pain. This helps restore an appropriate gap between the vertebrae that surround the diseased disc, eliminating the pain caused during movement of the affected part.

Increase in the incidence of complications associated with the spine is one of the factors expected to increase health care costs worldwide. Other major factors are rise in the incidence of neurological diseases and neck deformities caused by obesity and injuries and increase in the incidence of degenerative disc disease, spondylolisthesis, prolapsed intervertebral circle, herniated disc, and spinal stenosis. The global spinal intervention market is expected to expand significantly in the next few years, due to high investments by major players in R&D activities and availability of government funds for promoting advanced technologies. However, lack of skilled, highly qualified, and well-experienced medical practitioners; high costs of surgery; and lack of awareness among patients about diagnosis are expected to be restraining factors for the global spinal intervention market during the forecast period.


The global spinal intervention market can be segmented based on surgery type, procedure type, technology, end-user, and region. Based on surgery type, the market can be segmented into open surgery and minimally invasive (MI) surgery. Due to occurrences of unsuccessful spinal surgeries, speedy research in newly developed techniques has been started to improve the outcome. Advancements in percutaneous techniques used in interventional procedures have lowered the invasive nature of the surgery. They have also avoided issues involved in open surgery such as infection and scarring. Based on procedure type, the global spinal intervention market can be classified into laminectomy, corpectomy, facetectomy, discectomy, and foraminectomy. Facetectomy is a procedure performed to remove the facet cartilage with the spine, which can promote easy fusion of bones. Non-fulfilment of this procedure can leave the facet articular cartilage inside, which may block the bone fusion by permitting the movement and contact between two cartilaginous surfaces in the particular part. Discectomy is a procedure allowing the removal of the herniated disc from the spinal canal. Laminectomy is a back surgery procedure performed to release the compressed spinal cord. Corpectomy is a procedure that helps relieve the damage caused to the vertebrae and the intervertebral discs. Foraminectomy is a spinal surgery procedure that decompresses the spinal nerves strained by the tissues, the disc material, or the bone that has narrowed the foraminal canal. Based on technology type, the global spinal intervention market can be classified into spinal fusion technology, spinal fixation technology, spinal non-fusion technology, annulus repair, dynamic stabilization, artificial disc replacement (or disc nucleus replacement), and vertebral compression fracture treatment. Based on end-user, the global spinal intervention market can be segregated into hospitals, research centers, and others.


Geographically, the global spinal intervention market can be divided into five major regions: North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. The market in North America is expected to lead the global market during the forecast period, due to increasing number of spinal surgeries in countries in the region.


Prominent players operating in the global spinal intervention market are Abbott Laboratories Ltd., Medtronic Inc, Zimmer Biomet Holdings Inc, Orthofix International N.V., Stryker Corporation, Globus Medical Inc, Boston Scientific Corporation, BioControl Medical Ltd., Synapse Biomedical Inc., and DePuy Synthes Inc.